News

First Subject Dosed with Gannex’s FXR Agonist ASC42 in a U.S. Phase I Trial
28/12/2020
Overweight and Obese Subjects Dosed with ASC41 Tablets in a Phase Ib Trial
22/12/2020
Gannex Received U.S. FDA Fast Track Designation for Its NASH Drug Candidate ASC42，an FXR Agonist
14/12/2020
Gannex Appoints Former Takeda Head of Liver Disease Clinical Development Melissa Palmer, MD as Chief Medical Officer
30/11/2020
ASC40 (TVB-2640) Phase 2 NASH Trial Completed Patient Enrollment in China
19/11/2020
Gannex Received U.S. IND Approval for Its NASH Drug Candidate ASC42，an FXR Agonist
12/10/2020
Ascletis’ Strategic Partner Sagimet to Present Data from Phase 2 FASCINATE-1 Trial of TVB-2640(ASC40) in NASH at AASLD’s The Liver Meeting Digital Experience™ 2020
10/10/2020
Gannex Filed US IND for Its NASH Drug ASC42, an FXR Agonist
14/09/2020
Gannex and Galmed Expand Development Programs For NASH Through Research Collaboration of Aramchol and ASC41 (THR-beta Agonist)
09/09/2020
Bridging Study in China Completed for NASH Drug Candidate ASC40
20/07/2020